Subscribe: Market Wire - Pharmaceuticals and Biotech: Equipment and Supplies
Added By: Feedage Forager Feedage Grade B rated
Language: English
cancer  clinical  company  december  marketwired dec  marketwired nov  marketwired november  marketwired  nov  technologies  today 
Rate this Feed
Rate this feedRate this feedRate this feedRate this feedRate this feed
Rate this feed 1 starRate this feed 2 starRate this feed 3 starRate this feed 4 starRate this feed 5 star

Comments (0)

Feed Details and Statistics Feed Statistics
Preview: Market Wire - Pharmaceuticals and Biotech: Equipment and Supplies

Marketwired - Equipment and Supplies

Marketwired - Equipment and Supplies

Last Build Date: Fri, 02 Dec 2016 11:06:25 EST

Copyright: Copyright: (C) Marketwired

VigiLanz Antimicrobial Stewardship Solutions Reduce Medication and Antimicrobial Expenditures, Drive Compliant Reporting at Leading Health Systems

Fri, 02 Dec 2016 10:00:00 EST

VigiLanz will highlight its antimicrobial stewardship offerings at the ASHP 2016 Midyear Clinical Meeting & Exhibition (Booth #1843)

Chief Science Officer Explains How Digipath Labs Enables True, Standardized Definition and Identification of Cannabis Strains

Fri, 02 Dec 2016 09:00:00 EST

LAS VEGAS, NV--(Marketwired - Dec 2, 2016) - Digipath, Inc. (OTCQB: DIGP) ("Digipath" or the "Company"), an independent cannabis lab testing and media firm, is pleased to provide an overview of Digipath Labs' vision for establishing classification of cannabis strains based on science and not colloquialism.

eWellness Announces Signing of Initial Third Party PT Clinic for its PHZIO Telemedicine Platform

Fri, 02 Dec 2016 08:45:00 EST

CULVER CITY, CA--(Marketwired - Dec 2, 2016) - eWellness Healthcare Corporation, (OTCQB: EWLL) is the first physical therapy telemedicine company to offer insurance reimbursable real-time distance monitored physical therapy (PT) treatments. The Company is pleased to announce the Company successfully signed its initial 3rd party PT clinic for the use of its PHZIO Tele- rehabilitation Platform. The agreement is with Back to Motion PT located in Denver Colorado. Back to Motion PT is one of our current universe of up to 30 beta site PT clinics to begin using our PHZIO system. The Company has a significant backlog of PT clinics who have indicated a high interest in using our PHZIO platform.

Avantor Unveils New Brand Identity

Thu, 01 Dec 2016 12:30:00 EST

Corporate logo and brand identity are reflective of Avantor's position as a growing, global supplier of high-purity life sciences and advanced technologies materials

The Alliance for Regenerative Medicine Commends Passage of 21st Century Cures Act, Inclusion of Regenerative Medicine-Specific Provisions

Thu, 01 Dec 2016 10:31:01 EST

WASHINGTON, DC--(Marketwired - Dec 1, 2016) -  The Alliance for Regenerative Medicine (ARM), the international advocacy organization representing the gene and cellular therapies and broader regenerative medicine sector, commends the U.S. House of Representatives' bipartisan passage of the 21st Century Cures Act.

Genetic Technologies Announces Offering of USD 6.0 Million of American Depository Shares

Thu, 01 Dec 2016 09:07:53 EST

MELBOURNE, AUSTRALIA--(Marketwired - Dec 1, 2016) - Genetic Technologies Limited (ASX: GTG) (NASDAQ: GENE) ("Company"), a molecular diagnostics company and provider of BREVAGenplus®, a first-in-class, clinically validated risk assessment test for sporadic (non-hereditary) breast cancer, today announced that it has entered into a definitive agreement with U.S. institutional investors, pursuant to which the investors have agreed to purchase an aggregate of 4,800,000 American Depositary Shares ("ADSs"), each representing one hundred and fifty (150) of the Company's Ordinary Shares, at a weighted average price of $1.25 per ADS. The Company will receive gross proceeds of approximately USD 6.0 million, before deducting customary offering expenses.

Oculus Innovative Sciences One Ups Itself, Meets Expectations Yet Again --

Thu, 01 Dec 2016 09:02:33 EST

REDONDO BEACH, CA--(Marketwired - Dec 1, 2016) -, a leading financial news and information portal offering free real time public company filing alerts, announces the publication of an article examining the turnaround efforts of Oculus Innovative Sciences (NASDAQ: OCLS).

GeoVax Observes World AIDS Day

Thu, 01 Dec 2016 09:00:00 EST

Everyone Encouraged to Get Tested for HIV

PharmaCyte Biotech Moves Closer to Enrolling Patients in Pancreatic Cancer Clinical Trial

Thu, 01 Dec 2016 09:00:00 EST

Company Aiming to Produce 6-Month Breakthrough Data

Crystal Research Associates, LLC Issues Executive Informational Overview on Hemispherx Biopharma, Inc.

Thu, 01 Dec 2016 08:30:00 EST

NEW YORK, NY--(Marketwired - December 01, 2016) - Crystal Research Associates, LLC announced today that it has issued an Executive Informational Overview® (EIO) on Hemispherx Biopharma, Inc. (NYSE MKT: HEB). The full 60-page report is available on Crystal Research Associates' website at

Axis Capital, Inc. Unveils Rebrand as "AMUR Equipment Finance"

Thu, 01 Dec 2016 08:18:00 EST

GRAND ISLAND, NE--(Marketwired - Dec 1, 2016) - Axis Capital, Inc. (Axis), one of North America's leading commercial equipment finance companies, has unveiled a new company name, logo and website -- rebranding as Amur Equipment Finance (AmurEF). As part of the company's 20th anniversary celebration, the corporate rebranding initiative reflects Amur Equipment Finance's vision for the future and affirms the core values which customers have grown to appreciate and trust.

Imagin Medical Completes Development of i/Blue Alpha B Prototype

Thu, 01 Dec 2016 08:00:00 EST

Imagin Medical is the developer of the ultrasensitive i/Blue Imaging System that will establish a new standard of care for urologists in detecting bladder cancer through endoscopes

Atossa Genetics to Present at the 9th Annual LD Micro Main Event Conference on December 7, 2016

Thu, 01 Dec 2016 08:00:00 EST

SEATTLE, WA--(Marketwired - Dec 1, 2016) - Atossa Genetics, Inc. (NASDAQ: ATOS) announced today that Kyle Guse, CFO and General Counsel, will be a featured presenter at the 9th annual LD Micro Main Event Conference on December 7, 2016 at 12:30pm PST, Track 4, at the Luxe Sunset Hotel in Los Angeles, CA. Management will also be available for one-on-one meetings on December 7 and 8, 2016.

Pieris Pharmaceuticals Appoints Claude Knopf as Chief Business Officer

Thu, 01 Dec 2016 08:00:00 EST

BOSTON, MA--(Marketwired - December 01, 2016) - Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for cancer and other diseases, today announced that it has appointed Claude Knopf as Senior Vice President and Chief Business Officer. Mr. Knopf is an accomplished executive in the biotech industry and brings to Pieris a demonstrable track record of success in strategy, corporate development, licensing, alliance management, marketing and sales spanning more than two decades.

Reliq Health Technologies Announces Patient Enrollment at the Feldman Institute in Louisiana for Pilot to Improve Access to Care for Interventional Pain Management Patients Post-Surgery

Thu, 01 Dec 2016 08:00:00 EST

VANCOUVER, BRITISH COLUMBIA--(Marketwired - Dec. 1, 2016) - Reliq Health Technologies Inc. (TSX VENTURE:RHT)(OTCQB:RQHTF) ("Reliq" or the "Company"), a technology company focused on developing innovative mobile health (mHealth) and telemedicine solutions for Community-Based Healthcare, is pleased to announce that it has begun enrolling patients for the pilot of its remote patient monitoring and secure communication solution with The Feldman Institute in Baton Rouge, Louisiana. The pilot will evaluate the use of Reliq Health's technology with patients who have been discharged home after interventional pain management surgery, or have returned to their homes between treatments at The Feldman Institute.

Stellar Biotechnologies to Present at the LD Micro Main Event Investor Conference

Thu, 01 Dec 2016 07:45:00 EST

LOS ANGELES, CA--(Marketwired - Dec 1, 2016) - Stellar Biotechnologies, Inc. (NASDAQ: SBOT), the leader in sustainable manufacture of a key protein utilized in multiple immunotherapy development pipelines targeting cancers, Alzheimer's and lupus, among other diseases, today announced that Stellar President and CEO Frank Oakes will present at the 9th Annual LD Micro Main Event investor conference to be held December 6-8, 2016 in Los Angeles, California.

Xtalks Announces its December 2016 Webinars

Thu, 01 Dec 2016 07:00:00 EST

TORONTO, ON--(Marketwired - December 01, 2016) - Upcoming free, educational webinars from Xtalks Life Sciences will feature topics on ICH E6 (R2),Sales Enablement Strategy, Immunotherapy, Big Data, Orphan Drug Development and Remote Monitoring.

Akers Biosciences Signs Distribution Agreement with First Check Diagnostics for Rapid Cholesterol Test

Thu, 01 Dec 2016 07:00:00 EST

THOROFARE, NJ--(Marketwired - Dec 1, 2016) - Akers Biosciences, Inc. (NASDAQ: AKER) (AIM: AKR.L) (the "Company" or "Akers Bio"), a developer of rapid health information technologies, has signed a distribution agreement with First Check Diagnostics, LLC ("First Check"), the major global diagnostic device and service provider, to serve as the exclusive distributor of the Company's rapid cholesterol self-test in the United States under their "First Check" brand.

ViaDerma, Inc. Clinical Studies Abroad in Europe, the Middle East and Asia Show Promising Results & Leads to Private Label Discussions

Wed, 30 Nov 2016 17:49:18 EST

Clinical Tests Show Dramatic Success of ViaDerma's Proprietary Delivery System Combined with FDA Approved Drugs for Wound Healing with Localized Wound Treatment -- This Leads to Early-Stage discussions with two Pharmaceutical Companies to Private Label Viabecline for Distribution in Europe, Asia, the Middle East, and North Africa

AXIM Biotech Looks to Unlock Value in 2017 --

Wed, 30 Nov 2016 12:00:00 EST

REDONDO BEACH, CA--(Marketwired - Nov 30, 2016) -, a leading financial news and information portal offering free real time public company filing alerts, announces an article discussing the major advancements in 2016 for AXIM Biotechnologies (OTCQB: AXIM) and the potential catalysts for the company in the upcoming year.

FDA Grants Diazyme 510(k) Clearance to Market Its Direct HbA1c (Enzymatic, On-Board Lysis) Assay for Clinical Chemistry Analyzers

Wed, 30 Nov 2016 09:00:00 EST

SAN DIEGO, CA--(Marketwired - November 30, 2016) - Diazyme Laboratories today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance to market its Direct HbA1c assay (Enzymatic, On-Board Lysis). HbA1c refers to glycated hemoglobin which occurs when hemoglobin, a protein within red blood cells that transports oxygen through the body, joins with glucose in the blood, thereby becoming glycated. Measuring HbA1c allows clinicians to get an overall picture of what a patient's average blood sugar levels have been over a period of months. This measurement is the gold standard in allowing clinicians to track patients with diabetes.

Manufacturing Leadership Forums Continue to Drive the Manufacturing Intelligence & Analytics Conversation

Wed, 30 Nov 2016 08:30:00 EST

Premiere Educational Events Concluded in Houston, Texas and Liverpool, England

Hamilton Thorne to Present at the 2016 LD Micro Main Event

Wed, 30 Nov 2016 08:30:00 EST

BEVERLY, MA and TORONTO, ON--(Marketwired - Nov 30, 2016) - Hamilton Thorne Ltd. (TSX VENTURE: HTL), a leading provider of precision instruments, consumables, software and services to the Assisted Reproductive Technologies (ART) and developmental biology research markets announced today announced that it will be presenting at the 9th annual LD Micro Main Event (, on Wednesday, December 6, 2016 at 2:30 pm Pacific Time (5:30 pm Eastern Time), at the Luxe Sunset Boulevard Hotel in Los Angeles, CA.

Helix BioPharma Corp. Accelerates Escalation of L-DOS47 Dosing in the U.S. Phase I Study

Wed, 30 Nov 2016 07:30:00 EST

TORONTO, ON--(Marketwired - Nov 30, 2016) - Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP), a clinical stage immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, is pleased to announce that after reviewing safety data from the Phase I/II study of L-DOS47 in non-squamous non-small cell lung cancer (LDOS002), the U.S. Food and Drug Administration ("FDA") has accepted an accelerated escalation scheme for L-DOS47 dosing in the U.S. Phase I study (LDOS001) up to 12µg/kg in combination with pemetrexed/carboplatin.

Nutritional High Corporate Update

Tue, 29 Nov 2016 13:43:15 EST

TORONTO, ONTARIO--(Marketwired - Nov. 29, 2016) - Nutritional High International Inc. (the "Company" or "Nutritional High") (CSE:EAT)(OTCQB:SPLIF)(FRANKFURT:2NU) announces the issuance of 315,000 stock options.

3M ESPE, DENTSPLY, Kerr Lead U.S. Dental Materials Market Due to Extensive Product Portfolios

Tue, 29 Nov 2016 12:30:52 EST

The U.S. dental materials market is projected to exceed $1.8 billion by 2023; the market includes dental cements, impression materials, direct and temporary restoratives, bonding agents, core build-up materials and anesthetic materials

Assemblée annuelle et extraordinaire de ZoomMed inc.

Tue, 29 Nov 2016 11:18:41 EST

MONTRÉAL, QUÉBEC--(Marketwired - 29 nov. 2016) - ZoomMed Inc. (TSX CROISSANCE:ZMD), annonce qu'elle a tenu son assemblée annuelle et extraordinaire des actionnaires le 29 novembre 2016.

Annual and Special Shareholders Meeting of ZoomMed Inc.

Tue, 29 Nov 2016 11:17:55 EST

MONTREAL, QUEBEC--(Marketwired - Nov. 29, 2016) - ZoomMed Inc. (TSX VENTURE:ZMD), announces it has held its Annual and Special Meeting of Shareholders on November 29, 2016.

The meeting was held for the purpose of:

HeartStitch(R) Presents Progressive Multi Center Data at Three Consecutive Clinical Congresses

Tue, 29 Nov 2016 09:48:05 EST

HeartStitch(R) Receives Rave Reviews During Three Consecutive Clinical Congresses Presenting Multi-Center Data and Performing Live Cases

PCI Synthesis Wins Best NCE Manufacturer in 2016

Tue, 29 Nov 2016 09:15:00 EST

2016 saw more industry recognition and new lines of business

Synthego's 12 Days of CRISPR Educates Scientists on CRISPR Genome Editing, Offers Grants Totaling $100,000 of Synthetic RNA

Tue, 29 Nov 2016 09:00:00 EST

Genome engineering solutions company provides tools and resources to help conduct successful CRISPR experiments

APC Invents Quantitative Method for Assessing Pattern of Antibody Labeling Impacting the Emerging, Rapidly Growing Market for Antibody-Drug Conjugates (ADC)

Tue, 29 Nov 2016 09:00:00 EST

VANCOUVER, BC--(Marketwired - November 29, 2016) - Advanced Proteome Therapeutics Corporation ("APC" or the "Company") (TSX VENTURE: APC) (FRANKFURT: 0E8) is pleased to announce that it has invented a measurable basis for evaluating antibody labeling that provides key information on the pattern of labeling. The technology provides a means of sorting labeling entities according to the degree of selective labeling resulting from modification of a target antibody for conjugation. The methodology produces a rank order of candidate antibodies carrying antibody connectors for linkage to payloads such as drugs or toxins which should aid decision-making in ADC development. Immense growth is expected for the therapeutic antibody market which is estimated to reach nearly $125 Billion USD by the year 2020 (The therapeutic monoclonal antibody market: Ecker et al. MAbs 2015, Volume 7, ppgs 9-14.).

Cell MedX (CMXC) Advances the Power of Microcurrents --

Tue, 29 Nov 2016 08:59:05 EST

REDONDO BEACH, CA--(Marketwired - Nov 29, 2016) -, a leading financial news and information portal offering free real time public company filing alerts, announces an article covering how Cell MedX Corp. (OTCQB: CMXC) has improved upon microcurrent technology with eBalance Pro and its progress towards commercialization.

BriaCell Files a Patent Application for its Companion Diagnostic Platform to complement BriaVax(TM)

Tue, 29 Nov 2016 08:30:00 EST

BERKELEY, CA and VANCOUVER, BC--(Marketwired - November 29, 2016) - BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX VENTURE: BCT) (OTCQB: BCTXF), a clinical-stage immuno-oncology company dedicated to the development of immuno-oncology treatments, is pleased to announce that it has filed a patent application with the U.S. Patent and Trademark Office (USPTO) as basis for potential future commercialization of tests for identifying patients with a high likelihood of responding favorably to the Company's lead product candidate, BriaVaxT, and/or other whole-cell cancer vaccines.

New Webinar Hosted by Xtalks with Late Breaking Data from the Society for Immunotherapy of Cancer 2016

Tue, 29 Nov 2016 07:00:00 EST

Combinatorial CD8+ and PDL1+ Cell Densities Correlate with Response and Improved Survival in NSCLC Patients Treated with Durvalumab

Genetic Technologies Limited and The University of Melbourne Enter into Exclusive Worldwide License Agreement to Develop Colorectal Cancer Risk Assessment Test

Tue, 29 Nov 2016 05:30:00 EST

MELBOURNE, AUSTRALIA--(Marketwired - Nov 29, 2016) - Genetic Technologies Limited (ASX: GTG) (NASDAQ: GENE) ("Company"), a molecular diagnostics company and provider of BREVAGenplus®, a first-in-class, clinically validated risk assessment test for sporadic (non-hereditary) breast cancer, today announced the signing of an exclusive worldwide license agreement with The University of Melbourne for the development and commercialisation of a novel colorectal cancer (CRC) risk assessment test.

Presentations at French Society of Plastic, Reconstructive and Aesthetic Surgery Reinforce Benefits of ReCell(R)

Mon, 28 Nov 2016 20:18:57 EST

NORTHRIDGE, CA and PERTH, AUSTRALIA and LONDON, UNITED KINGDOM--(Marketwired - Nov 28, 2016) - Avita Medical Ltd (ASX: AVH) (OTCQX: AVMXY), a regenerative medicine company specializing in new treatments for wounds and skin defects, said today that three presentations about the clinical benefits of its product ReCell® had been delivered at the French Society of Plastic, Reconstructive and Aesthetic Surgery meeting, which took place in Paris, France on 24-26 November.

Sermonix Pharmaceuticals to Present Poster on Physician Perceptions of Menopausal SERMs at San Antonio Breast Cancer Symposium

Mon, 28 Nov 2016 16:45:44 EST

COLUMBUS, OH--(Marketwired - Nov 28, 2016) - Sermonix Pharmaceuticals LLC, a specialty pharmaceutical company focused on the development and commercialization of female-specific oncology products, today announced that its poster on physician perceptions of estrogen agonist/antagonists in menopausal health has been accepted for presentation at the San Antonio Breast Cancer Symposium (SABC).

InspireMD to Present at LD Micro Main Event on December 6

Mon, 28 Nov 2016 16:01:00 EST

BOSTON, MA--(Marketwired - Nov 28, 2016) - InspireMD, Inc. (NYSE MKT: NSPR) (NYSE MKT: NSPR.WS) ("InspireMD" or the "Company"), a leader in embolic prevention systems (EPS), neurovascular devices and thrombus management technologies, today announced that Chief Financial Officer Craig Shore will present at the LD Micro 9th Annual Main Event on Tuesday, December 6, 2016 at 7:30 a.m. PT in Los Angeles, California. Mr. Shore will provide a corporate overview and discuss the Company's proprietary MicroNetT technology, which has been developed to address key issues found with current stenting options.

ACCUREXA, INC. (ACXA) and Other Medical Device Companies Add Value for Patients and Investors

Mon, 28 Nov 2016 14:00:00 EST

NEW YORK, NY--(Marketwired - November 28, 2016) - Accurexa, Inc. (OTCQB: ACXA), a small-cap biotech focused on chemotherapy and immunology, is an up-and-coming leader in the neurological therapy space. Currently, Accurexa is working on the targeted delivery of such therapies, specifically the direct delivery of chemotherapeutics that effectively and safely cross the blood-brain barrier,

Endonovo Signs Term Sheet for $5 Million to Redeem All Outstanding Convertible Notes and Prepare to Uplist Its Common Stock

Mon, 28 Nov 2016 12:29:10 EST

Financing to be Used for the Development of a Portfolio of Treatments for Vascular Diseases and Ischemic Injuries Using Endonovo's Immunotronics Platform

Successful Completion of Private Placement

Mon, 28 Nov 2016 10:23:11 EST

VANCOUVER, BC--(Marketwired - Nov 28, 2016) -

Progressive Care Increases Revenue by 33% to $1.6 Million during October 2016

Mon, 28 Nov 2016 09:31:56 EST

MIAMI, FL--(Marketwired - November 28, 2016) - Progressive Care Inc. (OTC PINK: RXMD), through its subsidiary Pharmco LLC, a South Florida health services organization and provider of prescription pharmaceuticals specializing in health practice risk management, compounded medications, the sale of anti-retroviral medications and related medication therapy management, and the supply of prescription medications to long term care facilities, announces robust October 2016 sales.

Hamilton Thorne Reports 18% Sales Increase for the Quarter Ended September 30, 2016

Mon, 28 Nov 2016 09:17:14 EST

BEVERLY, MA and TORONTO, ON--(Marketwired - Nov 28, 2016) - Hamilton Thorne Ltd. (TSX VENTURE: HTL), a leading provider of precision instruments, consumables, software and services to the Assisted Reproductive Technologies (ART) and developmental biology research markets today reported operational and financial results for the quarter and nine months ended September 30, 2016.

mCig Division Expands International Market

Mon, 28 Nov 2016 09:00:00 EST

Signs Agreement for European Distribution worth $2M over Next Three Years

Lion Biotechnologies Announces New Manufacturing Services Agreement with WuXi AppTec

Mon, 28 Nov 2016 08:00:00 EST

SAN CARLOS, CA--(Marketwired - November 28, 2016) - Lion Biotechnologies, Inc. (NASDAQ: LBIO), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte technology (TIL), announced today that it has entered into a new three-year Manufacturing Services Agreement (MSA) and related statements of work with WuXi AppTec, Inc. (WuXi AppTec) to manufacture and perform services related to the manufacture of the Company's autologous cell therapy products.

AVIS AUX MÉDIAS : OTTAWA -- Nous vous invitons à soumettre un projet dans la catégorie « Médias »

Mon, 28 Nov 2016 07:59:33 EST

OTTAWA, ON--(Marketwired - 28 novembre 2016) -

MEDIA ADVISORY: OTTAWA -- We invite you to submit a project in the Media Category

Mon, 28 Nov 2016 07:56:43 EST

OTTAWA, ON--(Marketwired - November 28, 2016) -

Upcoming Webinar to Examine Remote Monitoring and Preparing for ICH-GCP E6(R2) at Investigator Sites

Mon, 28 Nov 2016 07:30:00 EST

TORONTO, ON--(Marketwired - November 28, 2016) - On Tuesday, December 13, 2016, Xtalks will host a complimentary webinar featuring presenters Andrew Mitchell, Life Sciences Lead at Intralinks and Dan Sfera, owner of multiple investigator sites, a CRA academy and renowned for his blog, The Clinical Trials Guru. This webinar will focus on how Investigator Sites are preparing for ICH-GCP E6(R2) especially with regards to remote monitoring, sponsor oversight and a risk-based approach to quality management at investigator sites.

Akers Biosciences Completes Clinical Trial for Rapid Diabetic Ketoacidosis Breath Test

Mon, 28 Nov 2016 07:00:00 EST

THOROFARE, NJ--(Marketwired - Nov 28, 2016) - Akers Biosciences, Inc. (NASDAQ: AKER) (AIM: AKR.L), ("Akers Bio" or the "Company"), a developer of rapid health information technologies, has completed a clinical trial for BreathScan® DKA, the first single-use, non-invasive breath test to rapidly screen for diabetic ketoacidosis, a potentially life-threatening complication of diabetes caused by a lack of insulin in the body.

ANGLE plc: Issue of Share Options

Mon, 28 Nov 2016 04:18:04 EST

GUILDFORD, SURREY--(Marketwired - Nov 28, 2016) - ANGLE plc (AIM: AGL) (OTCQX: ANPCY)

Zecotek Closes Second Tranche of Non-Brokered Private Placement

Fri, 25 Nov 2016 18:02:54 EST

SINGAPORE--(Marketwired - November 25, 2016) -